Development of Perthes' Disease in a 3-Year-Old Boy with Idiopathic Thrombocytopenic Purpura and Antiphospholipid Antibodies

Ura, Yoko; Hara, Toshiro; Mori, Yoshimoto; Matsuo, Muneaki; Fujioka, Yūko; Kuno, Tateo; Okue, A.; Miyazaki, Sumio

doi:10.3109/08880019209006399

Cited by 19 publications

(6 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There have been some case reports on LA or APLA in children suffering from a diversity of extracerebral diseases (7,50,51,52,67) and cerebral manifestations, such as chorea (18, 61, 69), hemidystonia (3), and stroke (17,30,47,53). The following report describes two children who suffered from TIA or stroke, and in whom APLA were detected during the acute phase of the ischemic event, and six children in whom APLA were found in follow-up controls between 6 weeks and 6 years after stroke.…”

Section: Antiphospholipid Antibodies In Strokementioning

confidence: 98%

Antiphospholipid Antibodies in Cerebrovascular Ischemia and Stroke in Childhood

et al. 1994

View full text Add to dashboard Cite

We report on eight children who suffered from cerebrovascular ischemia or stroke at the age of 2 or up to 11 years. Antiphospholipid antibodies (APLA) were detected in two cases during the ischemic event and in six cases during follow-up examinations (after six weeks or within a span of six years). In two patients multiple stenoses of basal cerebral arteries were found; one of them suffered from moyamoya syndrome. The acute hemiplegia in one patient was linked to an asymptomatic mycoplasmal infection and APLA. In three cases, one of the parents was also APLA-positive. Seven patients were treated with acetylsalicylic acid, and in four cases immunoglobulin infusions were given. Transient ischemic attacks subsided after the child with the moyamoya syndrome received immunoglobulins. No effect of medication could be established in the other children. The concept of the antiphospholipid syndrome is still evolving. As none of the common risk factors pertaining to strokes in adults apply to children, pediatric research may offer a suitable platform for specific investigations on the causal, pathogenetic role of APLA. We propose that all children suffering from stroke or transient ischemic attacks should be tested for APLA.

show abstract

Section: Antiphospholipid Antibodies In Strokementioning

confidence: 98%

Antiphospholipid Antibodies in Cerebrovascular Ischemia and Stroke in Childhood

et al. 1994

View full text Add to dashboard Cite

show abstract

“…Gallistl et al [31] detected these abnormalities in only 9% of 44 patients. LCPD was reported in a 3-year-old patient with idiopathic thrombocytopenic purpura and aPL [32]. aPL were not systematically searched for in patients with LCPD.…”

Section: Osteonecrosis In Pediatric Patients With Apsmentioning

confidence: 98%

Orthopedic Involvement in Antiphospholipid Syndrome

Gorshtein

Levy

2007

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

Antiphospholipid syndrome (APS) is a common autoimmune disease, manifested by vascular thrombosis and fetal loss in the presence of antiphospholipid antibodies. Orthopedic involvement is a relatively novel and under-recognized feature of APS. In this article we review the association of primary, secondary, and catastrophic APS with diverse orthopedic conditions, including osteonecrosis in adult and pediatric patients, bone marrow necrosis, nontraumatic fractures, and some other disorders.

show abstract

“…81 Ura et al described a 3-year-old patient with idiopathic thrombocytopenic purpura (ITP) presenting with Perthes' disease. 82 Patient tested positive for aCL and LA. Interestingly, both antibodies disappeared on partial remission of ITP.…”

Section: Avn In Selected Apl-positive Casesmentioning

confidence: 99%

Musculoskeletal manifestations of the antiphospholipid syndrome

Noureldine

Khamashta

Merashli

et al. 2016

Lupus

View full text Add to dashboard Cite

The scope of clinical and laboratory manifestations of the antiphospholipid syndrome (APS) has increased dramatically since its discovery in 1983, where any organ system can be involved. Musculoskeletal complications are consistently reported in APS patients, not only causing morbidity and mortality, but also affecting their quality of life. We reviewed all English papers on APS involvement in the musculoskeletal system using Google Scholar and Pubmed; all reports are summarized in a table in this review. The spectrum of manifestations includes arthralgia/arthritis, avascular necrosis of bone, bone marrow necrosis, complex regional pain syndrome type-1, muscle infarction, non-traumatic fractures, and osteoporosis. Some of these manifestations were reported in good quality studies, some of which showed an association between aPL-positivity and the occurrence of these manifestations, while others were merely described in case reports.

show abstract

Development of Perthes' Disease in a 3-Year-Old Boy with Idiopathic Thrombocytopenic Purpura and Antiphospholipid Antibodies

Cited by 19 publications

References 6 publications

Antiphospholipid Antibodies in Cerebrovascular Ischemia and Stroke in Childhood

Antiphospholipid Antibodies in Cerebrovascular Ischemia and Stroke in Childhood

Orthopedic Involvement in Antiphospholipid Syndrome

Musculoskeletal manifestations of the antiphospholipid syndrome

Contact Info

Product

Resources

About